long intergenic non-protein coding RNA 1447Genealiases: []
Q-omics provides the consensus-scored LINC01447 profile across patient tissues and cancer cell-line models. LINC01447 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, LINC01447 is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, LINC01447 RNA expression shows 7,977 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BRCA, LUAD, and TGCT as cancer lineages where LINC01447 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01447 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01447 survival associations across molecular data types. LINC01447 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01447 RNA expression–survival associations across cancer types. High LINC01447 expression shows unfavorable associations in BRCA, LGG, KIRC, UCEC and THYM, but favorable associations in LUAD. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .033). Together, the overview and detailed table identify BRCA as the clearest survival context for LINC01447 RNA expression.
This table summarizes LINC01447 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01447. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01447 shows lower tumor expression in LUAD, KIRP, LUSC, KICH, THCA and KIRC. The LUAD box plot shows higher LINC01447 RNA expression in normal versus tumor tissue (log2 FC = −0.502, t-test p < 0.001).
This table shows molecular features associated with LINC01447 in patient tissues and cancer cell lines. In patient samples, LINC01447 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
